¼¼°èÀÇ Ç÷¾×¾Ï Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, ¾÷°è ºÐ¼® : Áúȯº°, Ä¡·á¹ýº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº° - ½ÃÀå ¿¹Ãø(2025-2034³â)
Hematologic Malignancies Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease, Therapy, End Use, and Region - Market Forecast, 2025-2034
»óǰÄÚµå : 1671137
¸®¼­Ä¡»ç : Polaris Market Research
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 116 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,250 £Ü 6,149,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,596,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ 20¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,250 £Ü 9,043,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, Ç÷¾×¾Ï Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 1,481¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀλçÀÌÆ®¿Í ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

Ç÷¾×¾Ï Ä¡·áÁ¦´Â ¹éÇ÷º´, ¸²ÇÁÁ¾, °ñ¼öÁ¾ µî Ç÷¾×¾ÏÀ» °ü¸®ÇÏ´Â µ¥ »ç¿ëµÇ´Â Ä¡·á¹ýÀ» ¸»ÇÕ´Ï´Ù. ÀÌµé ¾ÏÀº Ç÷¾×, °ñ¼ö, ¸²ÇÁ°è, ºñÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡¸ç, Àü¹®ÀûÀÎ Ä¡·á Á¢±ÙÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¹éÇ÷º´, ¸²ÇÁÁ¾, °ñ¼öÁ¾°ú °°Àº Ç÷¾×¾ÏÀÇ ¹ßº´·ü Áõ°¡¿Í Ä¡·á ¿É¼ÇÀÇ ¹ßÀü¿¡ ÈûÀÔ¾î Ç÷¾×¾Ï Ä¡·áÁ¦ ½ÃÀå Á¡À¯À²ÀÌ Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î´Â CAR-T ¼¼Æ÷ Ä¡·áÁ¦, ´ÜŬ·ÐÇ×ü µî ¸é¿ªÄ¡·áÁ¦ÀÇ ºÎ»ó°ú ºÎÀÛ¿ëÀÌ Àû°í º¸´Ù Á¤È®ÇÑ Ä¡·á¸¦ Á¦°øÇϴ ǥÀû Ä¡·áÁ¦ÀÇ Ã¤Åà Ȯ´ë°¡ ²ÅÈü´Ï´Ù. ¶ÇÇÑ, º´¿ë¿ä¹ý °³¹ß, ¸ÂÃãÀÇ·á, ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ È®´ë µî ±âÁ¸ Ä¡·á¹ýÀ» ´ëüÇÒ ¼ö ÀÖ´Â ºñ¿ë È¿À²ÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ºñÁî´Ï½º ±âȸµµ âÃâµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇöÀç ÁøÇà ÁßÀÎ ¿¬±¸, ÀÓ»ó½ÃÇè, »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀº ½ÃÀåÀÇ ±â¼ú Çõ½ÅÀ» Áö¼ÓÀûÀ¸·Î ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿Ü·¡ Ä¡·á·ÎÀÇ ÀüȯÀ» ÅëÇÑ È¯ÀÚ Á¢±Ù¼º Çâ»ó, Ä¡·á ÀúÇ×¼º °¨¼Ò¿¡ ´ëÇÑ ³ë·ÂÀº Àüü ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ÇâÈÄ ¸î ³â µ¿¾È Áö¼ÓÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

Ç÷¾×¾Ï Ä¡·áÁ¦ ½ÃÀå : ºÐ¼® °³¿ä

¹éÇ÷º´Àº ¸¸¼º ¸²ÇÁ¼º ¹éÇ÷º´(CLL), ±Þ¼º °ñ¼ö¼º ¹éÇ÷º´(AML) µî ÁúȯÀÇ ³ôÀº À¯º´·ü·Î ÀÎÇØ ½ÃÀå Á¡À¯À² 1À§¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. Ç¥Àû Ä¡·áÁ¦ °³¹ßÀÌ Å©°Ô ÁøÀüµÇ¸é¼­ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ¸²ÇÁÁ¾Àº CAR-T ¼¼Æ÷ Ä¡·á¿Í °°Àº ¸é¿ª¿ä¹ýÀÇ Ã¤Åà Áõ°¡·Î ÀÎÇØ °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â ºÐ¾ßÀÔ´Ï´Ù.

¸é¿ªÄ¡·á´Â Ç÷¾×¾Ï Ä¡·áÁ¦ ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖÀ¸¸ç, CAR-T ¼¼Æ÷ Ä¡·á¿Í ´ÜŬ·ÐÇ×ü°¡ Ç÷¾×¾Ï Ä¡·áÀÇ º¯È­¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Á¤¹ÐÄ¡·á°¡ Ç÷¾×¾Ï ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ°í ºÎÀÛ¿ëÀ» °¨¼Ò½ÃŰ¸é¼­ Ç¥Àû Ä¡·áÁ¦°¡ °¡Àå ºü¸¥ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù.

º´¿ø ¾à±¹Àº CAR-T ¼¼Æ÷ Ä¡·á, È­Çпä¹ý µî º¹ÀâÇÑ Ä¡·á¹ýÀ» ½ÃÇàÇÏ´Â µ¥ ÀÖ¾î ÇÙ½ÉÀûÀÎ ¿ªÇÒÀ» ¼öÇàÇϱ⠶§¹®¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¼Ò¸Å ¾à±¹Àº °æ±¸¿ë Ç×¾ÏÁ¦ ¹× ÀçÅà ġ·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ÈûÀÔ¾î °¡Àå ºü¸£°Ô ¼ºÀåÇϰí ÀÖ´Â ºÐ¾ßÀÔ´Ï´Ù.

ºÏ¹Ì´Â ³ôÀº Ä¡·á Á¢±Ù¼º, ¼±ÁøÈ­µÈ ÀÇ·á ÀÎÇÁ¶ó, »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ ±ÔÁ¦Àû Áö¿øÀ¸·Î ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¾Ï ¹ßº´·ü Áõ°¡, ÀÇ·á Á¢±Ù¼º Çâ»ó, Ä¡·á Çõ½Å¿¡ ´ëÇÑ ÅõÀÚ·Î ÀÎÇØ °¡Àå ºü¸£°Ô ¼ºÀåÇϰí ÀÖ´Â Áö¿ªÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ºÐ¼® ¹æ¹ý

Á¦4Àå Ç÷¾×¾Ï Ä¡·áÁ¦ ½ÃÀå ÀλçÀÌÆ®

Á¦5Àå ¼¼°èÀÇ Ç÷¾×¾Ï Ä¡·áÁ¦ ½ÃÀå : Áúȯº°

Á¦6Àå ¼¼°èÀÇ Ç÷¾×¾Ï Ä¡·áÁ¦ ½ÃÀå : Ä¡·á¹ýº°

Á¦7Àå ¼¼°èÀÇ Ç÷¾×¾Ï Ä¡·áÁ¦ ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

Á¦8Àå ¼¼°èÀÇ Ç÷¾×¾Ï Ä¡·áÁ¦ ½ÃÀå : Áö¿ªº°

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ±â¾÷ °³¿ä

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The hematologic malignancies therapeutics market size is expected to reach USD 148.15 billion by 2034, according to a new study by Polaris Market Research. The report "Hematologic Malignancies Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease (Leukemia, Lymphoma, and Myeloma), Therapy, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Hematologic malignancies therapeutics refer to the medical treatments used to manage blood cancers, which include leukemia, lymphoma, and myeloma. These cancers affect the blood, bone marrow, lymphatic system, or spleen and require specialized therapeutic approaches. The hematologic malignancies therapeutics market share is experiencing significant growth, driven by increasing incidence rates of blood cancers such as leukemia, lymphoma, and myeloma, alongside advancements in treatment options. Key drivers include the rise of immunotherapies, such as CAR-T cell therapies and monoclonal antibodies, as well as the growing adoption of targeted therapies that offer more precise treatment with fewer side effects. Opportunities are emerging in the development of combination therapies, personalized medicine, and the expansion of biosimilars, providing cost-effective alternatives to traditional treatments. Additionally, ongoing research, clinical trials, and regulatory approvals for new therapies continue to drive innovation in the market. Trends such as a shift toward outpatient care increased patient access, and a focus on reducing treatment resistance contribute to the market's overall expansion, positioning it for continued growth in the coming years.

Hematologic Malignancies Therapeutics Market Report Highlights

Leukemia dominates the market in terms of market share due to the high prevalence of conditions such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Significant advancements in targeted therapies are driving its growth. However, lymphoma is the fastest growing segment, driven by the increasing adoption of immunotherapies such as CAR-T cell therapies.

Immunotherapy holds the largest hematologic malignancies therapeutics market share, with CAR-T cell therapies and monoclonal antibodies playing a crucial role in transforming the treatment of hematologic malignancies. Targeted therapies are registering the fastest growth as precision treatments continue to improve outcomes and reduce side effects in blood cancer patients.

Hospital pharmacies hold the largest market share due to their central role in administering complex treatments such as CAR-T cell therapies and chemotherapy. Retail pharmacies are the fastest growing segment, supported by the rising demand for oral oncolytics and at-home treatment options.

North America dominates the market due to high treatment accessibility, advanced healthcare infrastructure, and regulatory support for new therapies. Asia Pacific is the fastest growing region, fueled by increasing cancer incidence, improving healthcare access, and investment in treatment innovations.

Polaris Market Research has segmented the hematologic malignancies therapeutics market report based on disease, therapy, end use, and region:

By Disease Outlook (Revenue-USD Billion, 2020 - 2034)

By Therapy Outlook (Revenue-USD Billion, 2020 - 2034)

By End Use Outlook (Revenue-USD Billion, 2020 - 2034)

By Regional Outlook (Revenue-USD Billion, 2020 - 2034)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Hematologic Malignancies Therapeutics Market Insights

5. Global Hematologic Malignancies Therapeutics Market, by Disease

6. Global Hematologic Malignancies Therapeutics Market, by Therapy

7. Global Hematologic Malignancies Therapeutics Market, by End Use

8. Global Hematologic Malignancies Therapeutics Market, by Geography

9. Competitive Landscape

10. Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â